---
title: "Gyre updates corporate presentation detailing pipeline, China strategy and regulatory progress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288405214.md"
description: "Gyre Therapeutics released an updated corporate presentation detailing pipeline progress, China strategy, and regulatory milestones. Key highlights include positive Phase 3 topline results for F351 in CHB-associated liver fibrosis and NMPA acceptance of its NDA by May 2026. The company emphasizes leveraging China operations to enhance R&D efficiency and reduce costs. Clinical updates show CG001419 advancing into Phase 1b expansion with no dose-limiting toxicities, while CG009301 is undergoing dose escalation."
datetime: "2026-06-02T10:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288405214.md)
  - [en](https://longbridge.com/en/news/288405214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288405214.md)
generator: "portal-rs"
---

# Gyre updates corporate presentation detailing pipeline, China strategy and regulatory progress

**Gyre made available an updated corporate presentation highlighting pipeline progress, China-enabled R&D efficiency and regulatory milestones including an NMPA acceptance for F351.**

**Key Highlights:**

-   Updated corporate presentation posted on Gyre’s website (furnished as Exhibit 99.1) under Regulation FD disclosure.
-   F351 (hydronidone) reported positive Phase 3 topline results for CHB-associated liver fibrosis and NDA accepted by NMPA in May 2026.
-   Gyre emphasizes China operations to accelerate discovery, validation and development and to reduce costs across R&D, manufacturing and commercialization.
-   Pipeline spans discovery to marketed products: ETUARY™ marketed, multiple degraders/DACs and candidates (CG923308, CG620953, CG001419, CG009301) in development.
-   Clinical updates: CG001419 progressed into Phase 1b expansion with no DLTs observed in first 22 patients; CG009301 dose escalation underway with no DLTs in first eight patients.

Original SEC Filing: GYRE THERAPEUTICS, INC. \[ GYRE \] - 8-K - Jun. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GYRE.US](https://longbridge.com/en/quote/GYRE.US.md)

## Related News & Research

- [GYRE: Global R&D engine advances novel degraders and DACs, funded by strong China commercial revenues](https://longbridge.com/en/news/297655933.md)
- [Gyre Therapeutics outlines protein degrader pipeline, China commercial outlook in corporate presentation](https://longbridge.com/en/news/297654775.md)
- [ZKH Group director Han Yunjie sells US$57,009 of common shares](https://longbridge.com/en/news/298717619.md)
- [IceCure wins China NMPA approval to market ProSense cryoablation system](https://longbridge.com/en/news/298589959.md)
- [Rezubio doses first cohort in Phase I trial of inhaled RZ-520](https://longbridge.com/en/news/298299102.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**